Map the system. Preserve the evidence. Test the handoff.
Source-backed reporting and analysis connected to the companies, capabilities, authorities, and operating domains it affects.
Siemens presents Opcenter Execution Pharma as an MES for master-batch-record-driven execution, electronic batch records, integration with production control, and review by exception. A shorter review is defensible only when event coverage, source-system boundaries, exception rules, reviewer authority, and unresolved data gaps are explicit.
ResearchSpace says RSpace can connect notebook records, sample information, instrument records, uploaded files, and external storage, and can bundle external files in exports. A portable research record still needs stable identities, exact versions, hashes, relationship history, permissions, export scope, validation, and a documented restore test.
Dotmatics presents an electronic lab notebook that can organize experimental records and support AI-assisted write-ups and analysis. Generated text can accelerate review, but it cannot establish that the source data, method, interpretation, attribution, or scientific conclusion is correct.
NIH requires applicable researchers to plan for managing and sharing scientific data and to comply with approved plans. The policy creates an evidence obligation, not a universal repository decision or proof that an ELN alone satisfies the plan.
FDA's CGMP records guidance says a paper chromatogram generally omits the injection sequence, instrument method, integration method, and audit trail associated with the result. A printable report can support review, but it cannot silently replace the retained electronic source record.
Version 2.0 broadens the buyer test from notebook authoring or file retention to planning, generation, processing, analysis, sharing, preservation, reuse, governance, infrastructure, standards, workforce, and community.
The OECD principles define a managerial quality-control system for covered non-clinical safety studies, while national programmes verify facility compliance through inspections and study audits. A platform cannot self-declare that status.
FDA good laboratory practice rules give the study director overall study control while requiring an independent quality assurance unit for each study. Laboratory systems should preserve both roles without letting workflow convenience erase the review boundary.
For drug CGMP laboratory records within its scope, 21 CFR 211.194 connects the sample, method, raw data, calculations, result, performer, and second-person review. A final result in a LIMS is not the complete record when the source observations and review path cannot be reconstructed.
The regulator's publication page preserves its GxP guidance while noting that OECD Advisory Document No. 22 takes precedence for GLP data integrity.
The official standard record helps device and platform teams compare service definitions, commands, properties, metadata, and communication while leaving safety, method, data, and operating assurance separate.
The official framework makes an important architecture distinction: storing a file, structuring scientific context, and aligning semantic terms are related but different responsibilities.
The official informatics record spans sample operations, experiment records, procedure execution, scientific-data management, analytics, and specialty workflows on one portfolio.
The current product record combines LIMS, ELN, and LES positioning with instrument and analytical-data connections, creating a useful system-boundary test for buyers.
The product page documents the current chromatography data-system family while buyers still need version-specific evidence for instruments, processing, controls, interfaces, migration, and retained records.
The official platform record centers ingest, engineering, harmonization, context, data products, and application access rather than replacing the LIMS, ELN, CDS, or instrument that creates an operational record.
